



## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 63067

**Title:** Recent advances in gastro-intestinal cancers

**Reviewer's code:** 02543955

**Position:** Peer Reviewer

**Academic degree:** FEBS, MD

**Professional title:** Associate Professor, Senior Researcher, Surgical Oncologist

**Reviewer's Country/Territory:** Germany

**Author's Country/Territory:** Switzerland

**Manuscript submission date:** 2021-01-28

**Reviewer chosen by:** Ya-Juan Ma

**Reviewer accepted review:** 2021-03-02 12:05

**Reviewer performed review:** 2021-03-07 14:56

**Review time:** 5 Days and 2 Hours

<b>Scientific quality</b>	<input checked="" type="checkbox"/> Grade A: Excellent [ ] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
<b>Language quality</b>	[ ] Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
<b>Conclusion</b>	[ ] Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection
<b>Re-review</b>	[ ] Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous [ ] Onymous Conflicts-of-Interest: [ ] Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

This interesting and informative review summarizes 13 phase III studies that were presented at last year's ASCO, ASCO-GI, ESMO and/or ESMO-GI. The manuscript is well written and concise. Minor points might be addressed: - Page 4, NRT-TOG 1010: The sentence "Participants on the experimental treatment arm received weekly trastuzumab during CXRT and then following surgery for 13 treatments." This might be rephrased since treatments is not related to surgery. - I would suggest to use "esophageal" instead of "oesophageal" throughout the whole manuscript - Results from the IDEA trial should be clarified. Some phrases might be misleading, e.g. "For patients treated with CAPOX 3 months OS was 82.1% compared to 81.2% in those receiving it for 6 months". - To gain more overview, a summary of the results of the studies in tables might be helpful.